BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schlaak M, Pickenhain J, Theurich S, Skoetz N, von Bergwelt-Baildon M, Kurschat P. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database Syst Rev 2013;:CD008908. [PMID: 23986525 DOI: 10.1002/14651858.CD008908.pub3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Fay CJ, Awh KC, LeBoeuf NR, Larocca CA. Harnessing the immune system in the treatment of cutaneous T cell lymphomas. Front Oncol 2022;12:1071171. [PMID: 36713518 DOI: 10.3389/fonc.2022.1071171] [Reference Citation Analysis]
2 Willemze R, Theurich S, Schlaak M. Indolent Cutaneous T-Cell Lymphomas. Hematologic Malignancies 2021. [DOI: 10.1007/978-3-030-55989-2_14] [Reference Citation Analysis]
3 Valipour A, Jäger M, Wu P, Schmitt J, Bunch C, Weberschock T. Interventions for mycosis fungoides. Cochrane Database Syst Rev 2020;7:CD008946. [PMID: 32632956 DOI: 10.1002/14651858.CD008946.pub3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
4 Stainthorpe A, Fleeman N, Houten R, Chaplin M, Boland A, Beale S, Dundar Y, McEntee J, Syndikus I. Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoecon Open 2020;4:563-74. [PMID: 32207075 DOI: 10.1007/s41669-020-00203-0] [Reference Citation Analysis]
5 Wobser M, Weber A, Glunz A, Tauch S, Seitz K, Butelmann T, Hesbacher S, Goebeler M, Bartz R, Kohlhof H, Schrama D, Houben R. Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells. J Hematol Oncol 2019;12:30. [PMID: 30885250 DOI: 10.1186/s13045-019-0719-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
6 Leuchte K, Schlaak M, Stadler R, Theurich S, von Bergwelt-baildon M. Innovative Behandlungskonzepte mit Modulation der Mikroumgebung beim kutanen T-Zell-Lymphom. Kompass Dermatol 2019;7:111-119. [DOI: 10.1159/000500890] [Reference Citation Analysis]
7 Berg S, Villasenor-Park J, Haun P, Kim EJ. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome. Curr Hematol Malig Rep 2017;12:234-43. [PMID: 28540671 DOI: 10.1007/s11899-017-0387-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ma H, Abdul-Hay M. T-cell lymphomas, a challenging disease: types, treatments, and future. Int J Clin Oncol 2017;22:18-51. [PMID: 27743148 DOI: 10.1007/s10147-016-1045-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
9 Herling M. Primär kutane Lymphome. SpringerReference Innere Medizin 2015. [DOI: 10.1007/978-3-642-54676-1_514-1] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]